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Abstract Lapatinib, an oral, reversible inhibitor of epi-
dermal growth factor receptor and human epidermal
growth factor receptor 2 (HER2) tyrosine kinase, has pro-
ven antitumor activity in HER2-positive metastatic breast
cancer (MBC). Nanoparticle albumin-bound paclitaxel
(nab-paclitaxel) is indicated for the treatment of breast
cancer after failure of combination chemotherapy for
metastatic disease or relapse within 6 months of adjuvant
chemotherapy. This was an open-label, single-arm, multi-
center, Phase II study to evaluate the efficacy and safety of
nab-paclitaxel plus lapatinib in women with HER2 over-
expressing MBC who had received no more than one prior
chemotherapeutic regimen. The primary efficacy endpoint
was the overall response rate (ORR). This was defined as
the percentage of patients having either a complete
response (CR) or partial response (PR). Secondary efficacy
endpoints included progression-free survival (PFS), overall
survival, duration of response (DoR), time to response
(TTR), and time to progression (TTP). Investigator-asses-
sed ORR was 53 % (n = 32, 95 % confidence interval
(CI): 40.7–66.0) with the majority of patient responses
demonstrating a PR (47 %). Four (7 %) patient responses
demonstrated a CR, and ten (17 %) a stable disease. The
median Kaplan–Meier estimate of investigator-assessed
PFS, DoR, TTR, and TTP was 39.7 weeks (95 % CI
34.1–63.9), 48.7 weeks (95 % CI 31.7–57.1), 7.8 weeks
(95 % CI 7.4–8.1), and 41 weeks (95 % CI 39.1–64.6),
respectively. Lapatinib 1,000 mg with nab-paclitaxel
100 mg/m2 IV is feasible with manageable and predictable
toxicity and an ORR of 53 % comparing favorably with
other HER2-based combinations in this setting.
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Introduction
Breast cancer is the most commonly diagnosed tumor type
in women in the United States with a significant proportion
developing metastatic disease [1]. Metastatic breast cancer
(MBC) is an incurable disease, and systemic treatment
This study was presented, in part, at the San Antonio Breast Cancer
Symposium, San Antonio, TX, December 6–10, 2011; the 45th
Annual Meeting of the American Society of Clinical Oncology,
Orlando FL, May 29–June 2, 2009.
D. A. Yardley (&)
Sarah Cannon Research Institute, Nashville, TN, USA
e-mail: dyardley@tnonc.com
D. A. Yardley
Tennessee Oncology, PLLC, Nashville, TN, USA
L. Hart
Florida Cancer Specialists, Fort Myers, FL, USA
L. Bosserman
Willshire Oncology Medical Group, La Verne, CA, USA
M. N. Salleh
Georgia Cancer Specialists, Atlanta, GA, USA
D. M. Waterhouse
OHC (Oncology Hematology Care), Cincinnati, OH, USA
M. K. Hagan
Virginia Cancer Care, Mechanicsville, VA, USA
P. Richards
Oncology & Hematology Associates of SW, Salem, VA, USA
M. L. DeSilvio  J. M. Mahoney  Y. Nagarwala
GlaxoSmithKline, Collegeville, PA, USA
123
Breast Cancer Res Treat (2013) 137:457–464
DOI 10.1007/s10549-012-2341-9
aims to prolong survival, control disease progression,
alleviate symptoms, and enhance patient quality of life.
Although early detection and improvements in therapy
have augmented survival rates in recent years (5-year rel-
ative survival is 99 % for localized disease and 84 % for
regional disease), the 5-year survival rates for patients with
distant-stage disease remains low at 23 % [1].
Control of several cellular processes in breast cancer is
dependent on the epidermal growth factor receptor (EGFR,
also known as ErbB) family, and members of this family
have been proposed as targets in cancer therapy. Amplifi-
cation of human epidermal growth factor receptor 2
(HER2/ErbB2) leads to increased receptor homo- and
hetero-dimerization and subsequent activation of down-
stream signaling pathways associated with cell prolifera-
tion, differentiation, survival, and angiogenesis [2]. Initial
studies indicated that 20–25 % of tumors in women with
early stage I–III breast cancers were HER2 positive [3, 4].
However, a larger and more recent study from Europe has
reported HER2-positive breast cancer rates in the range of
13–19 % [5] which has both prognostic and predictive
implications [3, 6].
HER2-positive tumors are associated with particularly
aggressive disease and a poor prognosis with shorter
overall survival (OS) and disease-free survival intervals
[3]. Studies have shown that HER2-positive tumors are
more likely to disseminate to major visceral sites as well as
the central nervous system (CNS) [7, 8].
Trastuzumab, a monoclonal antibody directed against
the HER2 receptor, has clinical activity in patients with
HER2-positive breast carcinoma and is widely used in
combination with cytotoxic agents [9–11]. A significant
number of patients with HER2-positive MBC who are
treated with trastuzumab experience symptomatic CNS
metastases, potentially due to ineffective penetration of
the CNS. Trastuzumab resistance may also develop,
limiting trastuzumab’s ability to maintain disease control
in the advanced as well as early stage disease settings
[12]. As such, alternative therapeutic strategies and
combinations need to be developed to target HER2
signaling.
Lapatinib (Tykerb/Tyverb, GlaxoSmithKline) is an
orally active small molecule that inhibits the tyrosine
kinase activity of HER2 and EGFR. Lapatinib has shown
clinical activity in combination with capecitabine in HER2-
positive tumors that progressed while on standard treat-
ment, including trastuzumab [13]. Lapatinib, in combina-
tion with capecitabine was approved in 2007 by the U.S.
Food and Drug Administration (US FDA) for the treatment
of patients with advanced or MBC with HER2-positive
tumors who have received prior therapy including an
anthracycline, a taxane, and trastuzumab [14]. Lapatinib in
combination with letrozole (an aromatase inhibitor) has
also been shown to be effective in the treatment of post-
menopausal women with hormone receptor-positive,
HER2-positive MBC [15]. In 2010, the US FDA granted
accelerated approval to lapatinib for use in combination
with letrozole for the treatment of patients with HER2-
positive MBC and for whom hormonal therapy is indicated
[14].
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel;
Abraxane for Injectable Suspension, Celgene Corpora-
tion) is a novel Cremophor EL-free, non-crystalline,
amorphous, albumin-bound nanoparticle formulation of
paclitaxel suspended in normal saline. It is associated with
a lower risk of hypersensitivity as well as an improved
toxicity profile, and has no requirements for premedication
compared with solvent-based paclitaxel [16]. Furthermore,
the neuropathy that frequently accompanies paclitaxel
administration was easily managed and resolved more
rapidly in patients treated with nab-paclitaxel [16]. Nab-
paclitaxel demonstrated significantly longer progression-
free survival (PFS), compared with docetaxel, in patients
with MBC [17, 18]. Nab-paclitaxel has been approved by
the US FDA in 2005 for the treatment of breast cancer after
failure of combination chemotherapy for metastatic disease
or relapse within 6 months of adjuvant chemotherapy.
Prior therapy should have included an anthracycline unless
clinically contraindicated [19].
In early as well as advanced HER2-positive breast
cancer, synergy between chemotherapy and HER2-directed
therapy (such as trastuzumab) has significantly improved
outcomes, including survival, compared with chemother-
apy alone [10, 11]. However, despite treatment with tax-
ane-based trastuzumab regimens in early stage disease,
disease progressions are still evident. The proven activity
of lapatinib in this setting (due to its differing mechanism
of action) demonstrates that it is a suitable option in HER2-
positive MBC. Unlike trastuzumab, it has been suggested
that lapatinib can cross the blood–brain barrier, providing a
rationale for testing lapatinib in patients with CNS metas-
tases [20, 21]. Studies have also shown that HER3 can be
transphosphorylated by p95 HER2 (a truncated version
lacking the extracellular domain) in HER2-overexpressing
breast cancer cell lines, and that this phosphorylation is
inhibited by lapatinib, but not trastuzumab [22]. A more
recent study demonstrated an OS benefit with lapatinib in
combination with trastuzumab for patients with HER2-
positive MBC [23]. Also, owing to the toxicity of solvent-
based paclitaxel, evaluation of lapatinib in conjunction
with nab-paclitaxel for the treatment of HER2-positive
MBC is warranted.
Presented here are the results of a single-arm, multi-
center Phase II study undertaken to determine the activity
of lapatinib plus nab-paclitaxel in the first- and second-line
setting in HER2-positive MBC.




This was an open-label, single-arm, multicenter, Phase II
study (NCT00709761) to evaluate the efficacy and safety of
nab-paclitaxel plus lapatinib in women with HER2-positive
MBC who had received no more than one prior chemothera-
peutic regimen in the metastatic setting. The planned enroll-
ment was 60 patients with a lead in evaluation of the first 10
patients for safety of this combination. A safety analysis of the
first ten enrolled patients treated for at least one cycle of the
initial doses of nab-paclitaxel (125 mg/m2 IV on Day 1, 8, and
15 every 28 days) in combination with lapatinib (1,250 mg
orally once daily on a continuous basis) in a 4-week cycle for a
planned minimum of six cycles was performed. However,
during the ongoing safety review of the first five patients,
Grade 3 toxicities were observed in all five patients (four with
neutropenia and one with neutropenic fever and diarrhea) and
the decision was made to reduce the dose of both study drugs.
All subsequent patients (n = 55) received nab-paclitaxel
(100 mg/m2 IV on Day 1, 8, and 15 every 28 days) in com-
bination with lapatinib (1,000 mg orally once daily on a
continuous basis) in a 4-week cycle for a minimum of six
cycles. If a complete response (CR) was obtained before six
cycles, the patient had to receive two additional cycles of the
combination regimen after which the CR was confirmed (a
minimum of four cycles). After six cycles, patients continued
to receive a daily dose of lapatinib 1,000 mg orally until
disease progression or withdrawal from study due to unac-
ceptable toxicity or consent withdrawal. Patients could also
continue to receive nab-paclitaxel after six cycles if there was
benefit without unacceptable toxicity.
Efficacy assessments were performed every 8 weeks and at
the end of investigational treatment. All patients are being
followed for survival. Lapatinib treatment delays of up to
2 weeks were permitted for resolution of toxicities, other than
in the event of protocol defined liver abnormalities, left ven-
tricular cardiac dysfunction, or interstitial pneumonitis. Only
one dose reduction of both lapatinib (to 750 mg) and nab-
paclitaxel (to 80 mg/m2) was permitted for related toxicity.
Safety assessments were performed throughout the study
and included physical examinations, Eastern Cooperative
Oncology Group (ECOG) performance status (PS), vital
signs, clinical laboratory evaluations, cardiac monitoring
(left ventricular ejection fraction function at 12-week inter-
vals for patients while receiving lapatinib), and recording of
adverse events (AEs) and serious AEs (SAEs).
Patient population
Female patients C18 years of age with histologically
confirmed HER2-positive invasive breast cancer (defined
as HER2 positive score [ 2.2] by fluorescence in situ
hybridization or 3? amplification by immunohistochem-
istry) who presented with de novo stage IV disease or had
stage IV disease at a relapse after curative-intent surgery
were enrolled in the study.
Patients were required to have received no more than
one prior chemotherapeutic regimen in the metastatic
setting. Prior endocrine therapy or trastuzumab treatment
in the neoadjuvant, adjuvant, or metastatic setting was
permitted. If a taxane had been previously administered,
progression must have occurred C12 months after com-
pletion of this treatment. Patients were also required to
have an ECOG PS of 0 or 1, and measurable disease,
according to Response Evaluation Criteria in Solid
Tumors version 1.0 guidelines [24]. A cardiac ejection
fraction of at least 50 %, as measured by echocardiogram
or multigated acquisition scan, within the institutional
range of normal was also essential. Patients with stable
CNS metastases (stable for at least 3 months) were eli-
gible if they were not taking steroids or enzyme-inducing
anticonvulsants. Bisphosphonate therapy for bone metas-
tases was allowed. However, treatment must have been
initiated prior to the first dose of study medication. Key
exclusion criteria included active cardiac, hepatic, or
biliary diseases, concurrent treatment with other antican-
cer or investigational agents, peripheral neuropathy of
Common Terminology Criteria for Adverse Events Grade
2 or greater, and diseases or surgeries affecting gastro-
intestinal function including malabsorption syndrome,
gastric resection, and uncontrolled inflammatory bowel
disease.
Study endpoints
The primary efficacy endpoint was overall response rate
(ORR), based on confirmed responses from investigator
assessment of best overall response. ORR was defined as
the percentage of patients having either a CR or partial
response (PR). Secondary efficacy endpoints included PFS
(defined as time from the start of treatment until the earliest
date of disease progression or death due to any cause, if
sooner), OS (defined as time from the start of treatment
until death due to any cause), duration of response (DoR)
(defined for the subset of patients who show a CR or PR—
time from first documented evidence of CR or PR until the
first documented sign of disease progression or death due
to any cause), and time to response (TTR) (defined for the
subset of patients who show a CR or PR as time from the
start of treatment until first documented evidence of PR or
CR, whichever is recorded first). When tumor response was
confirmed at a repeat assessment, the TTR was taken to be
the first time the response was observed. Time to pro-
gression (TTP) (defined as time from the start of treatment
Breast Cancer Res Treat (2013) 137:457–464 459
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until the earliest date of disease progression, or death due
to breast cancer, if sooner) was also included as another
secondary efficacy endpoint.
Statistical analyses
All efficacy analyses were conducted on the intent-to-treat
population, which comprised all patients who received at
least one dose of study drug. Exact binomial 95 % confi-
dence interval (CI) for the overall response rate was used.
The Kaplan–Meier estimate for the median PFS, OS, DoR,
TTR, and TTP were summarized, along with approximate
95 % CI, if there were a sufficient number of events. The
estimate of the standard error was computed by Green-
wood’s formula [25]. The study was not designed for
inference testing. Sample-size considerations were based
entirely on feasibility. No statistical hypotheses were tes-
ted, and the focus was to estimate the ORR who received
no more than 1 prior treatment for HER2-positive MBC. A
sample size of 60 was targeted to insure that the lower limit




From July 2, 2008 to January 5, 2011, 60 patients were
enrolled and treated at 14 centers in the United States.
Patient demographics and prior anticancer treatments are
summarized in Table 1. The median time from initial
diagnosis (any stage) was 28.9 months; 25 % of the
patients had previously received one prior regimen in the
metastatic setting and 57 % of patients had previously
received neo/adjuvant therapy. Disease burden at baseline
is shown in Table 2. The most common sites of metastatic
disease were lymph nodes, followed by the lung, liver,
bone, and breast.
Primary efficacy results: overall tumor response rate
Lapatinib ? nab-paclitaxel was efficacious with respect to
investigator-assessed ORR (53 % [n = 32, 95 % CI
40.7–66.0]) with the majority of patients having a PR (28;
47 %), four patients (7 %) a CR and ten patients (17 %)
showing stable disease (SD) (Table 3). A total of ten
patients had unknown responses. These were patients who
withdrew on or before the first response assessment time
point of 8 weeks with no tumor assessments available with
the exception of one patient who withdrew at week 9 due
to diarrhea and refused to have the bone scans.
Secondary efficacy results
The median Kaplan–Meier estimate of investigator-asses-
sed PFS was 39.7 weeks (95 % CI 34.1–63.9) (Table 3).
As of the data cut-off, 13 patients (22 %) had died.
Therefore, the median OS was not reached as the data were
not mature (i.e., [75 % of the patients were censored for
the endpoint). The median Kaplan–Meier estimate of
investigator-assessed TTR and DoR was 7.8 weeks (95 %
CI 7.4–8.1) and 48.7 weeks (95 % CI 31.7–57.1) for
patients who responded (CR or PR). The Kaplan–Meier
estimate for median TTP was 41 weeks (95 % CI
39.1–64.6). TTP was similar to PFS in this study as the
majority of PFS events (either progression or death due to
any cause) were disease progressions (28 out of 30). Two
PFS events were deaths due to causes other than breast
cancer and were considered a competing risk for the TTP
analysis.
Lapatinib and nab-paclitaxel exposure
The median duration of exposure to lapatinib was
5.6 months (range, 0–19 months). The mean daily lapati-
nib dose was 893.1 mg. Approximately half of the study
population (31 patients; 52 %) completed six cycles of
treatment with nab-paclitaxel, which was the duration of
treatment specified in the protocol. A total of 13 patients
(22 %) continued to participate in the study for further
cycles of treatment. In total, 73 lapatinib dose interruptions
occurred in 34 patients (57 %) were of short duration (51/
73 interruptions were B7 days in duration), and were
mainly due to non-hematologic toxicities (52 %). Twenty-
six reductions in the dose of lapatinib were made in 24
patients (40 %) and were also mainly due to non-hemato-
logic toxicities (85 %). Twenty-four doses of nab-paclit-
axel were delayed in 15 patients (25 %), and were most
commonly due to non-hematologic toxicity (42 %). Six-
teen dose reductions of nab-paclitaxel occurred in 13
patients (22 %) mainly due to hematologic toxicities
(56 %). Doses of nab-paclitaxel were missed by 33 patients
(55 %) and the majority of these patients missed one or two
doses (53 missed doses in total). The most common reason
for missing a dose was non-hematologic toxicity (47 %).
Safety
The most commonly reported AEs were diarrhea, fatigue,
nausea, and rash (Table 4). The maximum toxicity grade of
the majority of frequently reported AEs was Grade 1 or 2.
Grade 3 diarrhea was reported at a frequency of 20 %,
contributing to a high overall frequency (62 %) of AEs
with a maximum toxicity Grade of 3. AEs of neutropenia
also reached a maximum toxicity Grade of 3 for 22 % of
460 Breast Cancer Res Treat (2013) 137:457–464
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patients. A total of five patients (8 %) experienced Grade 4
events (diarrhea, nausea, fatigue, febrile neutropenia, and
hypokalemia) and all these AEs were considered treatment-
related.
Eighteen patients (30 %) reported SAEs (Table 5). The
most frequently reported SAEs were dehydration (n = 3;
5 %) and diarrhea (n = 3; 5 %).
Forty-nine patients (82 %) discontinued study treatment,
predominantly due to disease progression (28 patients), and
10/49 patients (17 %) experienced an AE that led to the
permanent discontinuation of study treatment (Table 6).
Overall, 13 deaths were reported in this study with the
primary cause of death due to breast cancer (n = 10/13;
17 %). Two patients (3 %) died due to SAEs (sudden
death, acute renal failure) which were considered to be
related to treatment. There were no clinically significant
changes in vital signs, body weight, and ECOG PS during
the study.
Discussion
The primary objective of this study was to determine the
ORR in patients with HER2-positive MBC who received
first-line or second-line treatment with lapatinib in com-
bination with weekly nab-paclitaxel. This study was not
designed for inference testing thus definitive conclusions
cannot be derived from the results. A clinical benefit was
observed for treatment with lapatinib plus nab-paclitaxel
with respect to investigator-assessed ORR in 32 patients
(53 %). The highest number of responses was PR (28
patients; 47 %). Four patients (7 %) had a CR and ten
patients (17 %) showed SD.
ORR in this study was lower compared with other
studies conducted to investigate paclitaxel and lapatinib
combination therapy. In a Phase III, multicenter, double-
blind, placebo-controlled study in which patients with
HER2-positive MBC (Stage IV) received treatment with
paclitaxel and either lapatinib or placebo (NCT00281658),
ORR was 69 % [26].
In a Phase II study in which 57 female patients with
HER2-positive MBC (Stage IV) were randomized to
receive paclitaxel and lapatinib (NCT00356811) ORR was
77 % [27]. These differences could be due in part to the
small sample size, confounded by the inclusion of both
first-line and second-line patients and the fact that ten
patients in this study had an unknown response (no tumor
assessments available).
The clinically meaningful activity observed in the pri-
mary endpoint was supported by investigator-assessed PFS,
where the median Kaplan–Meier estimate of PFS was
39.7 weeks. These results are consistent with those of other
trials evaluating paclitaxel and lapatinib combination
Table 1 Patient demographics and prior anticancer therapies
Characteristic Lapatinib ? nab-
paclitaxel (n = 60)a
Age, years
Median (range) 56 (28–80)
HER2 status, n (%)
FISH? (with or without IHC?) 37 (62)
IHC 3? (only) 23 (38)
ER/PgR status, n (%)
ER? and/or PgR? 34 (57)
ER- and PgR- 26 (43)
Line of metastatic treatment, n (%)
First-line 45 (75)
Second-line 15 (25)
Median time since first diagnosis, months 28.9

















ER estrogen receptor, FISH fluorescence in situ hybridization, HER2
Human epidermal growth factor receptor 2, IHC immunochemistry,
PgR progesterone receptor
a All patients were female
Table 2 Disease burden at time of study enrollment
Lapatinib ? nab-
paclitaxel (n = 60)




Sites of disease, n (%)




Breast (de novo Stage IV) 12 (20)
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therapy. In two similar studies, the median PFS were
9.7 months (41.7 weeks) (NCT00281658) [26] and
47.9 weeks (NCT00356811) [27].
The median duration of lapatinib and nab-paclitaxel
treatment was 24.3 and 24 weeks, respectively. These data
are comparable to results from a randomized, multicenter,
double-blind, placebo-controlled, 2-Arm, Phase III Study
of lapatinib in combination with paclitaxel in subjects
previously untreated for advanced or MBC (NCT0007527
0) [28]. In this study, the median duration of lapatinib
treatment was 19.9 weeks, and the median duration of
paclitaxel treatment was 15.1 and 16.1 weeks in the pac-
litaxel-lapatinib and paclitaxel-placebo arms, respectively.
The maximum toxicity grade of the majority of AEs was
Grade 3 or less, and most resolved without sequelae. For
hematologic toxicities, Grade 3 neutropenia and anemia
was observed in 22 and 2 % of patients, respectively,
which was lower compared with 35 and 4 % observed in
the lapatinib plus paclitaxel study (NCT00281658) [26].
However, the non-hematologic toxicities observed in this
study were consistent with the NCT00281658 study [26].
Grade 3 diarrhea, rash, and fatigue were reported by 20, 5,
and 8 % of the patients, respectively, in this study com-
pared with 20, 4, and 2 % in the NCT00281658 study.
Although Grade 3 AEs of diarrhea and neutropenia were
reported by 20 and 22 % of patients, respectively, low
numbers of patients withdrew due to these AEs (7 % due to
Table 3 Efficacy results (ITT population)
Characteristic Lapatinib ? nab-
paclitaxel (n = 60)
Overall response rate (ORR)
Response rate (CR ? PR), n (%) (95 % CI) 32 (53) (40.7–66.0)







Patients, n (%) 60 (100)
Progressed or died due to any cause 30 (50)
Censored, follow-up ended 19 (32)
Censored, follow-up ongoing 11 (18)b
Kaplan–Meier estimate for PFS (weeks)
Median (95 % CI) 39.7 (34.1–63.9)
TTR
Patients, n (%) 32 (53)
Kaplan–Meier estimate for TTR (weeks)
Median (95 % CI) 7.8 (7.4–8.1)
DoR
Patients, n (%) 32 (53)
Progressed or died due to any cause 17 (53)
Censored, follow-up ended 4 (13)
Censored, follow-up ongoing 11 (34)b
Kaplan–Meier estimate for DoR (weeks)
Median (95 % CI) 48.7 (31.7–57.1)
TTP
Patients, n (%) 60 (100)
Progressed or died due to breast cancer 28 (47)
Censored, died due to other cause 2 (3)
Censored, follow-up ended 19 (32)
Censored, follow-up ongoing 11 (18)b
Kaplan–Meier estimate for TTP (weeks)
Median (95 % CI) 41.0 (39.1–64.6)
CI confidence interval, CR complete response, DoR duration of
response, ITT intent-to-treat, PD progressive disease, PFS progres-
sion-free survival, PR partial response, SD stable disease, TTR time to
response, TTP time to progression
a Patients who withdrew before the first response assessment. Patients
with unknown responses were treated as non-responders
b At the time of this reporting, there were 11 patients still ongoing on
lapatinib monotherapy treatment
Table 4 AEs with [15 % incidence by maximum toxicity grade
(ITT population)
Adverse events Number of subjects (%)
Lapatinib ? nab-paclitaxel (n = 60)
Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea (n = 54) 38 30 20 2
Fatigue (n = 41) 40 18 8 2
Nausea (n = 39) 38 23 2 2
Rash (n = 29) 25 18 5 0
Alopecia (n = 24) 15 25 0 0
Vomiting (n = 23) 25 8 5 0
Anemia (n = 22) 17 18 2 0
Neutropenia (n = 22) 5 10 22 0
Neuropathy peripheral
(n = 21)
20 12 3 0
Edema peripheral (n = 16) 15 12 0 0
Cough (n = 15) 20 5 0 0
Dyspnea (n = 15) 15 5 5 0
Decreased appetite (n = 15) 10 13 2 0
Constipation (n = 13) 20 2 0 0
Epistaxis (n = 13) 22 0 0 0
Nail disorder (n = 13) 13 8 0 0
Dehydration (n = 12) 0 13 7 0
Weight decreased (n = 11) 10 7 2 0
Pyrexia (n = 11) 15 3 0 0
Insomnia (n = 11) 15 3 0 0
Dyspepsia (n = 10) 15 2 0 0
Pain in extremity (n = 10) 12 5 0 0
Dysgeusia (n = 10) 13 3 0 0
AE adverse event, ITT intent-to-treat
462 Breast Cancer Res Treat (2013) 137:457–464
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diarrhea, none due to neutropenia). SAEs were reported by
30 % of patients. The most frequently reported SAEs were
dehydration (5 %) and diarrhea (5 %). Two patients died
during the study due to SAEs (sudden death in a patient
with a medical history of cardiac arrhythmias, and acute
renal failure in a patient with a medical history of uncon-
trolled diabetes).
This study established a dose regimen of nab-paclitaxel
(100 mg/m2 IV on Day 1, 8, and 15 every 28 days) in
combination with lapatinib (1,000 mg orally once daily on
a continuous basis) in a 4-week cycle as a feasible treat-
ment for HER2-positive MBC with manageable and pre-
dictable toxicity. The incidence and severity of AEs for the
combination treatment was considered to be consistent
with the known safety profiles of lapatinib and nab-pac-
litaxel. Overall, the data in this study are consistent with
those reported for other studies of lapatinib in combination
with paclitaxel. Although this study was not designed for
inference testing, the results suggest a promising signal of
efficacy and no new safety signals.
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